PNC-27

PNC-27 is a chimeric synthetic peptide that combines a p53-derived sequence (residues 12-26 of human p53, the tumor-suppressor protein) with the membrane-active "penetratin" sequence from the Antennapedia homeodomain protein. The resulting peptide has the striking property of selectively killing cancer cells by physically disrupting their plasma membrane, while leaving normal cells largely intact. The mechanism appears to depend on the abnormal presentation of HDM-2 (human MDM2, the p53-regulating ubiquitin ligase) on the surface of cancer cells — a feature absent or much less prominent on normal cells.

In preclinical studies, PNC-27 has shown direct tumoricidal activity across a broad range of cancer cell types in vitro (breast, prostate, lung, leukemia, lymphoma, pancreatic, melanoma) and in animal xenograft models. The selectivity for cancer-cell membrane lysis is mechanistically interesting and distinct from conventional cytotoxic chemotherapy. The peptide has been developed primarily by Matthew Pincus's group at the SUNY Downstate Health Sciences University.

Despite over a decade of academic preclinical work, PNC-27 has not achieved meaningful clinical translation. There have been no published large-scale human clinical trials, and the compound exists primarily as a research tool. It is sold by some research-chemical vendors. Use outside of formal cancer-research protocols carries unquantified risks and should not be attempted as a wellness intervention — this is not a peptide for self-experimentation.

PNC-27 was developed by Matthew Pincus's group at SUNY Downstate Health Sciences University, building on earlier research into p53-derived peptides for cancer therapy. Initial reports of selective cancer-cell killing emerged in the early 2000s. The mechanism involving HDM-2 surface expression on cancer cells was elaborated through subsequent publications. The compound has been the subject of multiple preclinical papers and at least one early-phase clinical observation, but no Phase 2 or 3 clinical program has matured.